Health and Healthcare
Eli Lilly Scores Solid Results in Psoriatic Arthritis Study
Published:
Last Updated:
Eli Lilly and Co. (NYSE: LLY) has announced positive results from its late-stage active psoriatic arthritis (PsA) study. This trial is the first completed large head-to-head superiority study in active PsA.
Specifically, the company’s study of Taltz (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira (adalimumab) in patients with active PsA who are biologic disease-modifying anti-rheumatic drug-naive.
At 24 weeks, patients treated with Taltz met the primary endpoint by demonstrating superiority in improving the signs and symptoms of active PsA compared to Humira, as measured by the proportion of patients simultaneously achieving at least a 50% reduction in disease activity, as defined by the American College of Rheumatology, as well as complete skin clearance as measured by the Psoriasis Area and Severity Index. Additionally, Taltz met the major secondary endpoints.
Overall, the safety profile of Taltz was consistent with previously reported results.
Looking ahead, Eli Lilly plans to submit detailed data from the SPIRIT-H2H study for disclosure at scientific meetings and in peer-reviewed journals in 2019.
Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Eli Lilly, commented:
The positive results from the SPIRIT-H2H trial reinforce that Taltz effectively treats the debilitating joint signs and symptoms of active psoriatic arthritis, while also providing skin clearance. These results provide evidence that Taltz can be used as a first-line biologic treatment for patients with active psoriatic arthritis.
Shares of Eli Lilly were last seen down about 2% at $109.77, in a 52-week range of $73.69 to $119.84. The consensus analyst price target is $115.00.
24/7 Wall St.Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.